Clinical efficacy of moxifloxacin in the treatment of Mycoplasma pneumonia
Abstract
Objective To evaluate the clinical efficacy of moxifloxacin in the treatment of Mycoplasma pneumonia. Methods The clinical efficacy for Mycoplasma pneumonia was analyzed in a randomized,controlled clinical trial of moxifloxacin compared with azithromycin plus ceftriaxone combination therapy in the treatment of community-acquired pneumonia. Results The efficacy rate was 96.4% in moxifloxacin group and 90.0% in the control group. Bacterial clearance rate in the two groups was 6/7 and 5/5,respectively. The difference between groups was not statistically significant (P0.05). The time to defervescence to 37.5 ℃ and hospital stay in moxifloxacin group [(3.2±1.5) d and (8.2±7.0) d] were shorter than those in the control group [(4.4±1.7) d and ( 10.0± 8.4 ) d](P0.05). The incidence of adverse drug reactions was 14.3% in moxifloxacin group and 26.7% in the control group. The difference was not statistically significant between the two groups (P0.05). Conclusions Efficacy of moxifloxacin monotherapy is equivalent to azithromycin plus ceftriaxone combination therapy in the treatment of Mycoplasma pneumonia. Moxifloxacin is better than the control therapy in terms of time to defervescence and hospital stay.
How strong is the evidence?
Evidence Hub reads this as a randomized trial. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Structural and topological analysis of thiosemicarbazone-based metal complexes: computational and experimental study of bacterial biofilm inhibition and antioxidant activity
- Toward better cures for Mycobacterium abscessus lung disease
- Challenges for global antibiotic regimen planning and establishing antimicrobial resistance targets: implications for the WHO Essential Medicines List and AWaRe antibiotic book dosing
- Design, Synthesis and In vitro Antitubercular Effect of New Chalcone Derivatives Coupled with 1,2,3‐Triazoles: A Computational Docking Techniques
- Upregulation of pmrA, pmrB, pmrC, phoQ, phoP, and arnT genes contributing to resistance to colistin in superbug Klebsiella pneumoniae isolates from human clinical samples in Tehran, Iran
- Whole-genome sequencing of clinical isolates of Citrobacter Europaeus in China carrying blaOXA−48 and blaNDM−1
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.